Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gardasil 9 efficacy in HIV-infected sexually active MSM
2015-004524-65Phase 4Terminated
- Sponsor
- Department of Infectious Diseases
- Start
- Oct 2015
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, sponsored by Department of Infectious Diseases. Primary endpoint: Change in prevalence of vaccine-type HPV infection. Started Oct 2015; status: terminated.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on 2015-004524-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004524-65.